Thursday, March 07, 2024 12:10:00 AM
DCVax’s mechanism of action leverages the immune system and therefore is intuitive to doctors
A. All antigens, information
- DCVax uses actual tumor lysate and importantly presents hundreds of DIFFERENT tumor antigens to the immune system
- Other drugs don’t
B. Efficacy, holistic approach
- Diversity in weapons: T cells, B cells, and antibodies
- Diversity in targets: activates unique cytotoxic T cells, helper T cells, B cells, and antibodies to target each different tumor antigen
- Robust immune memory: after killing the cancer, some T cells and B cells will become immune memory cells and remain
- Other drugs don’t
C. Naturally is not toxic
- Immature T cells and B cells travel thru the thymus and spleen. This process naturally screens out and destroys the self-reactive (autoimmune, toxicity) immune cells.
- Other drugs don't
D. Renaissance in how cancer is treated
- Today doctors have a “drug” that does not cure and must balance efficacy against toxicity
- Tomorrow doctors will have a DCVax “vaccine”, so their focus can then include optimizing a total therapy, including quality of life
The prospect of cancer cure is what all cancer patients desire most
A. DCVax as a vaccine
- Creating a more robust immune memory equates to cure and prevention
- Highly efficacious, non-toxic profile
- Other drugs are not
B. DCVax may possibly vaccinate against Second Primary Cancers
- 19% of cancer patients get a second cancer sometime in their life (unrelated to their first cancer). https://pubmed.ncbi.nlm.nih.gov/24857148/
- Dr. Bosch made this interesting point. Many of the tumor antigens found on the GBM tumor lysate were also the same tumor antigens found in other cancers
- Hypothesis is a DCVax enhanced immune memory can protect against other cancers, especially for those with genetic or family predisposition to a certain cancer.
- Other drugs don't
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM